22-24 September 2015, San Diego, CA, USA
We invite you to learn of the latest achievements on all major aspects of the polymyxin antibiotics. Colistin and polymyxin B are last therapeutic options for treatment of life-threatening infections caused by Gram-negative ‘superbugs’, including Pseudomonas aeruginosa, Acinetobacter baumannii , and Klebsiella pneumoniae. Since the 1st International Conference on Polymyxins in 2013 (Prato, Italy), significant progress has been made in the clinical use and pharmacology of polymyxins, in particular understanding how they should be dosed in particular types of patients, identification of the risk factors for nephrotoxicity and its mechanisms, and discovery of novel polymyxin-like antibiotics.
The conference will feature cutting-edge presentations by internationally leading clinicians, scientists, and regulatory agency representatives on topics including:
| Polymyxins and the Prato consensus |
|
Nephrotoxicity of polymyxins: The Achilles Heel |
| Gram-negative problem: Polymyxins in an age of new antibiotics |
|
Polymyxin combinations: Why and how? |
| Clinical use of colistin and polymyxin B: What have we learned? |
|
Discovery of new improved polymyxins: What is in the pipeline? |
| Optimized dosing of colistin and polymyxin B in patients: Are they from the same mold? |
|
Regulatory and industry issues and actions |
| MIC measurement and breakpoints: Update since 2013 |
|
Time travel: 60 years of polymyxins and the road ahead |
Organizing Committee: Co-Chairs Jian Li (Australia) and Keith Kaye (USA)
| Robert Bonomo, USA |
|
Jason Pogue, USA |
| Otto Cars, Sweden |
|
Vincent Tam, USA |
| William Couet, France |
|
Ursula Theuretzbacher, Austria |
| Mike Dudley, USA |
|
Brian Tsuji, USA |
| Johan Mouton, Netherlands |
|
Paul Tulkens, Belgium |
| Roger Nation, Australia |
|
John Turnidge, Australia |
| David Paterson, Australia |
|
Tony Velkov, Australia |
Program and presentations
22.-24. October 2014, Vienna, Austria
In the face of increasing antimicrobial resistance and the lack of new agents it has become clear that we need new strategies. One of these must be to revisit old antibiotics to make sure that we are using them correctly and to their full potential as well as to find out if one or several of them can help alleviate the pressure on more recent agents. On 22.-24. October 2014, Vienna played host to a major expert conference, convened by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the PK/PD study group, the antibiotic policy study group, EUCAST and the EU funded AIDA project. International researchers, academics, representatives from pharmaceutical companies and national medical and regulatory agencies explored the potential and pitfalls of using old revived antibiotics to tackle the growing global threat of antimicrobial resistance.
The three day conference, ‘Reviving Old Antibiotics’ has attracted participation from almost 300 delegates from 45 countries. The expert panel and the delegates have identified and agreed a number of key actions which need to be taken urgently, if old antibiotics are to be used effectively:
- To identify and gain consensus on candidates amongst old generations of antibiotics that are most needed to fight multi-drug resistant infections
- For candidate antibiotics, to establish current quantities, global availability and dispersal, quality, appropriateness for human and non-human use, and to carry out the necessary studies to fill the knowledge gaps
- To engage in a co-ordinated effort to disseminate and communicate to all stakeholders – including governments, donors, academics, researchers, health professionals and the pharmaceutical industry - to build support and gain consensus on the need for rapid action on exploring the benefits of using off-patent antibiotics to tackle antimicrobial resistance.
A full report from the conference, with recommendations and a plan of action, will be published shortly.
Programme
Press release after the conference
Photos
Austrian Radio and Television (ORF), Chinese CCTV-Xinhua (in English)
September 9, 2013,8:30 AM - 6:00 PM, Four Seasons Hotel in Denver, CO, USA (one day prior to ICAAC)
Registration and abstract submission are now possible! Abstract submission deadline: July 12, 2013.
Free registration for young investigators with an accepted abstract.
_______________________________________________________________________________________
1st International Workshop on Clinical Pharmacology of Antifungal Drugs and Fungal Diseases
26 April 2013 in Berlin, Germany, preceding the ECCMID 2013
This one-day international abstract-driven scientific and educational workshop will consist of invited lectures, oral abstract and clinical case presentations and a poster viewing session. ________________________________________________________________________________________
2 - 4 May, 2013, Monash Centre in Prato, Italy
Colistin and polymyxin B became available in the clinic in the 1950s but fell out of favor, mainly due to concerns about their potential to cause kidney toxicity. They have now come back into use as ‘last line' antibiotics for the treatment of infections caused by Gram-negative pathogens that are resistant to other available antibiotics. During the first several decades after they began to be used, there was little information on how to dose them most effectively. Over the last several years, substantial progress has been made in understanding how to optimize their clinical use.
Program and presentations
